Notice of Proposed Sale · 144
Ligand Pharmaceuticals Incorporated
LGNDNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- LIGAND PHARMACEUTICALS INCORPORATED
- Issuer CIK
- 0000886163
- SEC file number
- 001-33093
- Phone
- 858-550-7500
- Person for whose account securities are to be sold
- ANDREW REARDON
- Relationships to issuer
- Officer
- Street
- 555 Heritage Drive, Suite 200
- City
- Jupiter
- State / country code
- FL
- Postal code
- 33458
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 10,000 | 3,160,900.00 | 20,041,061 | 07/01/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/01/2026 | Exercise of Stock Options | Issuer | 10,000 | N | 07/01/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| 10b5-1 Sales for ANDREW REARDON | Common | 06/01/2026 | 5,000 | 1,135,315.50 |
| 10b5-1 Sales for ANDREW REARDON | Common | 05/01/2026 | 5,000 | 1,156,555.50 |
Seller — prior-sale row 1, entry 1
- Name
- 10b5-1 Sales for ANDREW REARDON
- Street
- 555 Heritage Drive, Suite 200
- City
- Jupiter
- State / country code
- FL
- Postal code
- 33458
Seller — prior-sale row 2, entry 1
- Name
- 10b5-1 Sales for ANDREW REARDON
- Street
- 555 Heritage Drive, Suite 200
- City
- Jupiter
- State / country code
- FL
- Postal code
- 33458
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Notice signature
- Notice date
- 07/01/2026
- Signed
- /s/ Andrew Reardon
- Plan adoption dates
- 11/24/2025
Company context
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.